## **AMENDMENTS TO THE CLAIMS**

- 1. 8. (Cancelled)
- 9. (Currently Amended) The compound of claim 1, being

N-(3,5-Difluoro-phenyl)-N'-[3-(1H-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;

N-(3,5-Dichloro-phenyl)-N'-[3-(1H-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;

N-(3,5-Bis-trifluoromethyl-phenyl)-N'-[3-(1H-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;

or a pharmaceutically acceptable salt thereof.

- 10. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 4 9, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
- 11. (Currently Amended) A method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to the blockade of chloride channels, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to claim 4 9, or a pharmaceutically acceptable salt thereof.
- 12. (Previously Presented) The method according to claim 11, wherein the disease, disorder or condition responsive to the blockade of chloride channels is a bone metabolic disease, an osteoclast related bone disease, or a disease, disorder or condition that is responsive to inhibition of angiogenesis.
  - 13. (Cancelled)

- 14. (New) The compound being N-(3,5-Difluoro-phenyl)-N'-[3-(1H-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea; or a pharmaceutically acceptable salt thereof.
- 15. (New) The compound being N-(3,5-Dichloro-phenyl)-N'-[3-(1H-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea; or a pharmaceutically acceptable salt thereof.
- 16. (New) The compound being N-(3,5-Bis-trifluoromethyl-phenyl)-N-[3-(1H-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea; or a pharmaceutically acceptable salt thereof.